Cancer Center Amsterdam, Department of Clinical Pharmacology and Pharmacy, VU University Medical Center, Amsterdam, The Netherlands.
Amsterdam Public Health research institute, VU University Medical Center, Amsterdam, The Netherlands.
Cancer Med. 2018 Jan;7(1):219-228. doi: 10.1002/cam4.1239. Epub 2017 Nov 23.
Adequate information on oral anticancer agent (OACA) use is an essential element of optimal cancer care. The present study aimed to get insight into the experiences of patients with information on OACA treatment and their characteristics regarding information dissatisfaction. Patients of four Dutch university hospitals using OACA participated in this observational study and completed the Satisfaction with Information about Medicines Scale (SIMS), EORTC Quality of Life Questionnaire-C30, Brief Illness Perception Questionnaire, and Beliefs about Medicines Questionnaire-Specific. Logistic regression analyses were used to determine factors associated with dissatisfaction with information. Patients (n = 208) using capecitabine (35%), lenalidomide (15%), imatinib (14%), temozolomide (12%), sunitinib (11%), thalidomide (5%), dasatinib (4%), erlotinib (2%), and nilotinib (2%) participated. Information on the following SIMS-items was inadequate: how OACA elicit their effect, how long it takes before treatment works, how to conclude that treatment is effective, the risk of side effects and its management, interference with sex life, drowsiness, interference with other medication and alcohol and what to do in case of a missed dose. Younger age, hematological malignancy, dyspnoea, positive perception of consequences of the cancer, low perception of treatment control, and indifferent attitude towards OACA were associated with dissatisfaction with information. In conclusion, a considerable number of patients would have appreciated receiving more information on specific issues relating to the consequences of OACA treatment such as the effects and side effects of OACA and the interference of treatment with various aspects of their daily life. Oncologists, hematologists, lung-oncologists and pharmacists may reconsider the provision of information on OACA treatment.
关于口服抗癌药物（OACA）使用的充分信息是优化癌症护理的重要组成部分。本研究旨在深入了解接受 OACA 治疗的患者的经验以及他们对信息不满的特征。四位荷兰大学医院的 OACA 患者参与了这项观察性研究，并完成了《药物信息满意度量表》（SIMS）、《EORTC 生活质量问卷-C30》、《简要疾病感知问卷》和《药物信念问卷-特异性》。逻辑回归分析用于确定与信息不满相关的因素。使用卡培他滨（35%）、来那度胺（15%）、伊马替尼（14%）、替莫唑胺（12%）、舒尼替尼（11%）、沙利度胺（5%）、达沙替尼（4%）、厄洛替尼（2%）和尼洛替尼（2%）的患者参与了本研究。以下 SIMS 项目的信息不足：OACA 如何发挥作用、治疗起效需要多长时间、如何确定治疗有效、副作用风险及其管理、对性生活的干扰、嗜睡、对其他药物和酒精的干扰以及在漏服药物时该怎么做。年龄较小、血液恶性肿瘤、呼吸困难、对癌症后果的积极认知、对治疗控制的低感知以及对 OACA 的冷漠态度与信息不满相关。总之，相当多的患者希望收到更多关于 OACA 治疗具体问题的信息，例如 OACA 的作用和副作用以及治疗对他们日常生活各个方面的干扰。肿瘤学家、血液学家、肺癌专家和药剂师可能需要重新考虑提供 OACA 治疗信息。
